The estimated Net Worth of Al Kraus is at least $453 Tysiąc dollars as of 6 February 2023. Mr. Kraus owns over 12,000 units of Cytosorbents Corp stock worth over $142,046 and over the last 14 years he sold CTSO stock worth over $0. In addition, he makes $311,000 as Independent Non-Executive Chairman of the Board at Cytosorbents Corp.
Al has made over 62 trades of the Cytosorbents Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 12,000 units of CTSO stock worth $31,800 on 6 February 2023.
The largest trade he's ever made was exercising 100,000 units of Cytosorbents Corp stock on 27 October 2014 worth over $4,000. On average, Al trades about 24,466 units every 42 days since 2011. As of 6 February 2023 he still owns at least 142,046 units of Cytosorbents Corp stock.
You can see the complete history of Mr. Kraus stock trades at the bottom of the page.
Al W. Kraus serves as Independent Non-Executive Chairman of the Board of the Company. Mr. Kraus has been a director of CytoSorbents since 2003, and has been Chairman of our Board since 2009. From 2003 through 2008, Mr. Kraus also served as our President and Chief Executive Officer. Prior to joining CytoSorbents, from 2001 to 2003, Mr. Kraus served as President and Chief Executive Officer of NovoVascular Inc., an early stage company developing coated stent technology. From 1996 to 1998, Mr. Kraus served as President and Chief Executive Officer of Althin Healthcare and from 1998 to 2000, served as President and Chief Executive Officer of Althin Medical Inc., a manufacturer of products for the treatment of end stage renal disease. While Chief Executive Officer of Althin Healthcare, he provided strategic direction and management for operations throughout the Americas. From 1985 through 1989, Mr. Kraus served as Chief Executive Officer of Victor Technologies, formerly known as Micronics, a computer company, and from 1979 to 1985, he was U.S. Subsidiary Manager and Chief Operating Officer of Gambro Inc., a leading medical technology and healthcare company. Mr. Kraus was the Chief Operating Officer of Gambro when it went public in the United States in an offering led by Morgan Stanley. Mr. Kraus holds a BS in Business Administration from St. Joseph’s University.
As the Independent Non-Executive Chairman of the Board of Cytosorbents Corp, the total compensation of Al Kraus at Cytosorbents Corp is $311,000. There are 7 executives at Cytosorbents Corp getting paid more, with Phillip Chan having the highest compensation of $1,404,380.
Al Kraus is 75, he's been the Independent Non-Executive Chairman of the Board of Cytosorbents Corp since 2009. There are 1 older and 10 younger executives at Cytosorbents Corp. The oldest executive at Cytosorbents Corp is Dr. Robert H. Bartlett, 82, who is the Co-Chairman of Cardiac Surgery Advisory Board & Consultant.
Al's mailing address filed with the SEC is C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540.
Over the last 16 years, insiders at Cytosorbents Corp have traded over $1,216,453 worth of Cytosorbents Corp stock and bought 832,447 units worth $1,058,402 . The most active insiders traders include James T. Gunton, Al Kraus oraz Phillip P. Chan. On average, Cytosorbents Corp executives and independent directors trade stock every 34 days with the average trade being worth of $41,883. The most recent stock trade was executed by Alan D. Sobel on 13 December 2023, trading 22,557 units of CTSO stock currently worth $30,001.
cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents' purification technologies are based on biocompatible, highly porous polymer beads
Cytosorbents Corp executives and other stock owners filed with the SEC include: